PENYUSUN:
Delfree Ramba
K1A1 12 059
PEMBIMBING:
Oleo.
2
A. PENDAHULUAN
abad ke-19, asalnya merujuk kepada kesenangan seksual dengan rasa sakit
dan penderitaan orang lain. Seiring waktu, istilah ini diperluas meliputi
kebanyakan tidak ikut dalam perilaku non seksual, sadistik dengan pasangan
digabungkan dalam DSM II, yang mana gejala PAPD termasuk menghalangi-
dan keras kepala di mana setiap hal tersebut menggambarkan sifat tidak suka
3
B. GANGGUAN KEPRIBADIAN SADISTIK DAN NEGATIFISTIK
SPD)
a) Definisi
lebih dari satu orang dan tidak hanya demi tujuan rangsangan seksual
(Myers, 2006).
b) Kriteria Diagnostik
orang lain. Perlu dicatat bahwa sementara SPD dan ASPD memiliki
4
1. Suatu pola perilaku kejam, merendahkan dan perilaku aggresif,
lain
tertentu)
kegiatan sosial)
5
h. Terpesona oleh kekerasan, senjata, bela diri, cedera, atau
penyiksaan)
c) Penanganan
akut dan kronik. Tujuan untuk penanganan perilaku agresif akut, yang
pada pasien yang tidak sabar, eliminasi untuk perilaku agresif untuk
1. Antipsikotik
6
terdapat bukti bahwa risperidon bisa menurukan agresi dalam
2. Litium
7
ditangani dengan litium atau plasebo selama 4 minggu. Hasil dari
3. Antikonvulsan
Barrat, 1997).
8
4. Selective Serotonin Reuptake Inhibitor (SSRI)
5. Beta Bloker
9
2. Gangguan Kepribadian Negatifistik/Pasif-Agresif (Negativistic
PAPD)
a) Definisi
kepala, tidak cakap yang disengaja dan pelupa. Dalam DSM III,
b) Kriteria Diagnostik
10
kepribadian digambarkan, dengan demikian diagnosis masih
okupasional,
orang lain.
(Hopwood, 2012).
c) Penanganan
mencari pereda gejala tanpa mencari tahu akar dari penyebab gejala
11
1. Klozapin
gejala negatif pada pasien defisit dan non defisit. Klozapin hanya
efektif untuk mengobati gejala negatif pada non defisit (Brier dkk,
1994).
1999).
2. Amisulpride
12
Satu penelitian mengevaluasi dua dosis olanzapin (5 dan 20
2006).
3. Asenafin
4. Antidepresan
(Singh, 2010).
5. Minosiklin
13
Minosiklin merupakan antibiotic tetrasiklin dengan
2013).
6. Agonis Dopamin
14
Lisdexamfetamine efektif untuk mengurangi gejala negatif pada
7. Agen kolinergik
dan plasebo pada gejala negatif pada PANSS (Singh dkk, 2012).
15
DAFTAR PUSTAKA
16
12. Loo, H dkk. Amisulpride versus Placebo in the Medium-Term Treatment of
the Negative Symptoms of Schizophrenia. British Journal Psychiatry. 1997.
170 : 18–22.
13. Lecrubier, Y dkk. The Treatment of Negative Symptoms and Deficit States
of Chronic Schizophrenia: Olanzapine Compared To Amisulpride and
Placebo in a 6-Month Double-Blind Controlled Clinical Trial. Acta
Psychiatrica Scandinavia. 2006. 114 : 319–327.
14. Levkovitz, Y, dkk. a Double-Blind, Randomized Study of Minocycline for
the Treatment of Negative and Cognitive Symptoms in Early-Phase
Schizophrenia. The Journal of Clinical Psychiatry. 2010. 71 : 138–149.
15. Malone, RP. A Double-Blind Placebo-Controlled Study of Lithium in
Hospitalized Aggressive Children and Adolescents With Conduct Disorder.
Archives of General Psychiatry. 2000. 57 (7) : 649-654
16. Moller, H.J. Amisulpride: Efficacy in The Management of Chronic Patients
with Predominant Negative Symptoms of Schizophrenia. European
Archives of Psychiatry and Clinical Neuroscience. 2001. (251) : 217–224.
17. Myers WC dkk. Sadistic Personality Disorder and Comorbid Mental Illness
in Adolescent Psychiatric Inpatients. Journal of American Psychiatry and
The Law. 2006. 34 (1) : 61-71
18. Rinne, T dkk. SSRI Treatment of Borderline Personality Disorder: a
Randomized, Placebo-controlled Clinical Trial for Female Patients with
borderline personality disorder. American Journal of Psychiatry. 2002 : 159
(12) : 2048–2054.
19. Rosenheck dkk. Impact of Clozapine on Negative Symptoms and on the
Deficit Syndrome in Refractory Schizophrenia. Department of Veterans
Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.
American Journal of Psychiatry. 1999. 156 : 88–93.
20. Potkin, S.G. dkk. Efficacy and Tolerability of Asenapine in Acute
Schizophrenia: a Placebo-Andrisperidone-Controlled Trial. Journal Clinical
Psychiatry. 2007. 68 : 1492–1500.
21. Kane, J.M. dkk. Armodafinil as Adjunctive Therapy in Adults with
17
Cognitive Deficits Associated with Schizophrenia: a 4-Week, Double-Blind,
Placebo-Controlled Study. The Journal of Clinical Psychiatry. 2010. 71 :
1475–1481.
22. Salzman C dkk. Effect of Fluoxetine on Anger in Symptomatic Volunteers
With Borderline Personality Disorder. Journal of Clinical
Psychopharmacology. 1995. 15 (1) : 23–29.
23. Singh, S.P. dkk. Efficacy of Antidepressants in Treating the Negative
Symptoms of Chronic Schizophrenia: Meta-Analysis. British Journal
Psychiatry. 2010. 197 : 174–179.
24. Amiri, A ddk. Efficacy of Selegiline Add On Therapy to Risperidone in the
Treatment of The Negative Symptoms of Schizophrenia: A Double-Blind
Randomized Placebo-Controlled Study. Human Psychopharmacology.
2008. 23 : 79–86.
25. Bodkin, J.A dkk. Treatment of Negative Symptoms In Schizophrenia And
Schizoaffective Disorder by Selegiline Augmentation of Antipsychotic
Medication. a Pilot Study Examining The Role of Dopamine. Journal
Nervous Mental Disorder. 1996. 184 : 295–301.
26. Bodkin, J.A dkk Double-blind, Placebo Controlled, Multicenter Trial Of
Selegiline Augmentation Of Antipsychoticmedication To Treat Negative
Symptoms In Outpatients With Schizophrenia. American Journal
Psychiatry 2005. 162 : 388–390.
27. Jungerman, T. dkk. Deprenyl Augmentation for Treating Negative
Symptoms of Schizophrenia: a Double-Blind, Controlled Study. Journal
Clinical Psychopharmacology. 1999. 19 : 522–525.
28. Lasser, R.A. dkk. Adjunctive Lisdexamfetamine Dimesylate Therapy in
Adult Outpatients with Predominant Negative Symptoms of Schizophrenia:
Open-Label and Randomized-Withdrawal Phases.
Neuropsychopharmacology. 2013.
29. Arbabi, M dkk. A Placebo-Controlled Study of the Modafinil Added to
Risperidone in Chronic Schizophrenia. Psychopharmacology. 2012. 220,
591–598
18
30. Singh, J dkk. Acetylcholinesterase Inhibitors for Schizophrenia. 2012.
Cochrane Database Syst. Rev. 1 (CD007967).
19